The dry AMD treatment market is experiencing unprecedented growth, driven by increasing disease awareness, rising prevalence of age-related eye cond ...

Eyecyte-RPE phase 1 study showed promising safety and efficacy, with no serious adverse events and significant vision ...

The trial evaluates the safety and efficacy of Eyecyte-RPE in patients with geographic atrophy secondary to dry age-related ...

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, ...

Eyecyte-RPE™ is a cryopreserved, allogeneic RPE cell suspension developed to replace damaged retinal cells and restore vision. Approved by CDSCO, the Phase 1 trial was conducted at AIIMS New ...

Eyecyte-RPE™, in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). All patients across three cohorts were dosed without any serious adverse events.

Geographic atrophy presents as a well-defined, round or oval area of hypopigmentation, indicating retinal pigment epithelium (RPE) and choriocapillaris atrophy. Several imaging techniques are used ...

Atrophic lesions were defined as a sub-RPE illumination value of ≥0.4 mm2 and assessed by 2 graders to determine the stage. Atrophy was classified as incomplete or complete outer retinal atrophy ...

This process is called atrophy. If your doctor looks at your retina ... doctor see a view of your retinal pigment epithelial cells (RPE). Those are cells that help your retina stay healthy ...

This is called atrophy. The areas or patches of dead and ... Inside your eye, you have cells called the retinal pigment epithelium (RPE). These cells are in the deepest part of your retina.

With geographic atrophy, RPE cells can’t clean out that waste, which leads to vision loss. Contrary to what some people think, it’s possible to develop geographic atrophy in just one eye.